6-chloro-5-amino-4-(3-chloro-2-fluorophenylamino)pyrimidine | 833451-52-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-chloro-5-amino-4-(3-chloro-2-fluorophenylamino)pyrimidine
• 英文别名: 6-chloro-N₄-(3-chloro-2-fluorophenyl)pyrimidine-4,5-diamine；6-chloro-4-N-(3-chloro-2-fluorophenyl)pyrimidine-4,5-diamine
• CAS: 833451-52-8
• 化学式: C₁₀H₇Cl₂FN₄
• 分子量: 273.097
• InChiKey: CGAGHUFRAAMTSQ-UHFFFAOYSA-N

物化性质

• 沸点：
  365.8±42.0 °C(Predicted)
• 密度：
  1.584±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-chloro-5-amino-4-(3-chloro-2-fluorophenylamino)pyrimidine 在 盐酸 、 magnesium sulfate 、 potassium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (3-chloro-2-fluoro-phenyl)-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-5-oxa-2,4,11-triazadibenzo[a,d]cyclohepten-1-yl]amine
  参考文献：
  名称：

  ((3-Chloro-2-fluoro-苯基)-[7-甲氧基-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5-oxa-2,4,11的有效制备-triaza-dibenzo(a,d)cyclohepten-1-yl]-amine) 用于体内研究

  摘要：

  摘要 开发了一种用于制备数克数量的高度官能化的 5,6-二氢-嘧啶并 [4,5-b][1,4] 氧氮杂 1a 的改进路线。这种新方法的特点是通过 2,4,5-三羟基-苯甲醛的区域选择性甲基化，然后是硫酸镁促进的环化进行适当的甲氧基处理。

  DOI：

  10.1080/00397910500377479
• 作为产物：
  描述：

  4,6-二氯-5-氨基嘧啶 、 3-氯-2-氟苯胺 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 以68%的产率得到6-chloro-5-amino-4-(3-chloro-2-fluorophenylamino)pyrimidine
  参考文献：
  名称：

  ((3-Chloro-2-fluoro-苯基)-[7-甲氧基-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5-oxa-2,4,11的有效制备-triaza-dibenzo(a,d)cyclohepten-1-yl]-amine) 用于体内研究

  摘要：

  摘要 开发了一种用于制备数克数量的高度官能化的 5,6-二氢-嘧啶并 [4,5-b][1,4] 氧氮杂 1a 的改进路线。这种新方法的特点是通过 2,4,5-三羟基-苯甲醛的区域选择性甲基化，然后是硫酸镁促进的环化进行适当的甲氧基处理。

  DOI：

  10.1080/00397910500377479

文献信息

• [EN] GLUCOSE TRANSPORT INHIBITORS<br/>[FR] INHIBITEURS DE TRANSPORT DE GLUCOSE
  申请人：BAYER PHARMA AG

  公开号：WO2015078799A1

  公开（公告）日：2015-06-04

  The present invention relates to chemical compounds of general formula (I), in which Z, Y1, Y2, Y3, R3, R4, R5, R6, m, and n are as given in the description and in the claims, and which effectively and selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

  本发明涉及一般式（I）的化合物，其中Z、Y1、Y2、Y3、R3、R4、R5、R6、m和n如描述和索赔中所述，并且有效地和选择性地抑制葡萄糖转运蛋白1（GLUT1），以制备所述化合物的方法，包括包含所述化合物的药物组合物和药物组合物，用于制造用于治疗或预防疾病的药物组合物的用途，以及在制备所述化合物中有用的中间化合物。
• Novel tricyclic azepine derivatives: Biological evaluation of pyrimido[4,5-b]-1,4-benzoxazepines, thiazepines, and diazepines as inhibitors of the epidermal growth factor receptor tyrosine kinase
  作者：Leon Smith、Wai C. Wong、Alexander S. Kiselyov、Sabina Burdzovic-Wizemann、Yunyu Mao、Yongjiang Xu、Matthew A.J. Duncton、Ki Kim、Evgueni L. Piatnitski、Jacqueline F. Doody、Ying Wang、Robin L. Rosler、Daniel Milligan、John Columbus、Chris Balagtas、Sui Ping Lee、Andrey Konovalov、Yaron R. Hadari

  DOI：10.1016/j.bmcl.2006.07.031

  日期：2006.10

  Novel tricyclic derivatives containing an oxazepine, thiazepine, or diazepine ring were studied for their EGFR tyrosine kinase inhibitory activity. While the oxazepines were in general more potent than thiazepines, the diazepines displayed somewhat different structure-activity relationships. Moreover, the diazepines, in contrast to the oxazepines, showed appreciable inhibitory activity against the KDR tyrosine kinase. Furthermore, both oxazepines and diazepines demonstrated significant ability to inhibit autophosphorylation of EGFR in DiFi cells (generally, IC50 values in the single-digit micromolar to submicromolar range). (c) 2006 Elsevier Ltd. All rights reserved.
• [EN] EGFR TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE EGFR
  申请人：IMCLONE SYSTEMS INC

  公开号：WO2005009384A2

  公开（公告）日：2005-02-03

  The invention encompasses compounds that inhibit, modulate, or regulate kinases, compositions that contain kinase inhibiting compounds, and methods of treating kinase-dependent diseases and conditions in subjects in need of such treatment. Also, the invention encompasses methods of making compounds that inhibit, modulate or regulate kinases.
• Efficient Preparation of ((3‐Chloro‐2‐fluoro‐phenyl)‐[7‐methoxy‐8‐(3‐morpholin‐4‐yl‐propoxy)‐10,11‐dihydro‐5‐oxa‐2,4,11‐triaza‐dibenzo(a,d)cyclohepten‐1‐yl]‐amine) for In‐Vivo Study
  作者：Hu Liu、Leon M. Smith、Yunyu Mao、Weitao Pan、Yong‐Jiang Xu、Sabina Burdzovic‐Wizeman、Matthew A. J. Duncton、Wai C. Wong

  DOI：10.1080/00397910500377479

  日期：2006.1

  Abstract An improved route for the preparation of highly functionalized 5,6‐dihydro‐pyrimido[4,5‐b][1,4]oxazepine 1a in multigram quantities was developed. This new methodology was highlighted by the proper methoxy disposition via a regioselective methylation of 2,4,5‐trihydroxy‐benzaldehyde followed by a magnesium sulfate–promoted cyclization.

  摘要 开发了一种用于制备数克数量的高度官能化的 5,6-二氢-嘧啶并 [4,5-b][1,4] 氧氮杂 1a 的改进路线。这种新方法的特点是通过 2,4,5-三羟基-苯甲醛的区域选择性甲基化，然后是硫酸镁促进的环化进行适当的甲氧基处理。